SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.


Journal

Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289

Informations de publication

Date de publication:
15 05 2021
Historique:
received: 23 09 2020
revised: 16 02 2021
accepted: 24 02 2021
pubmed: 12 3 2021
medline: 7 4 2021
entrez: 11 3 2021
Statut: ppublish

Résumé

As the COVID-19 pandemic continues, there is an imminent need for rapid diagnostic tools and effective antivirals targeting SARS-CoV-2. We have developed a novel bioluminescence-based biosensor to probe a key host-virus interaction during viral entry: the binding of SARS-CoV-2 viral spike (S) protein to its receptor, angiotensin-converting enzyme 2 (ACE2). Derived from Nanoluciferase binary technology (NanoBiT), the biosensor is composed of Nanoluciferase split into two complementary subunits, Large BiT and Small BiT, fused to the Spike S1 domain of the SARS-CoV-2 S protein and ACE2 ectodomain, respectively. The ACE2-S1 interaction results in reassembly of functional Nanoluciferase, which catalyzes a bioluminescent reaction that can be assayed in a highly sensitive and specific manner. We demonstrate the biosensor's large dynamic range, enhanced thermostability and pH tolerance. In addition, we show the biosensor's versatility towards the high-throughput screening of drugs which disrupt the ACE2-S1 interaction, as well as its ability to act as a surrogate virus neutralization assay. Results obtained with our biosensor correlate well with those obtained with a Spike-pseudotyped lentivirus assay. This rapid in vitro tool does not require infectious virus and should enable the timely development of antiviral modalities targeting SARS-CoV-2 entry.

Identifiants

pubmed: 33706157
pii: S0956-5663(21)00159-7
doi: 10.1016/j.bios.2021.113122
pmc: PMC7921772
pii:
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Luciferases EC 1.13.12.-
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113122

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Références

Anal Chem. 2003 Apr 1;75(7):1584-9
pubmed: 12705589
Nat Methods. 2006 Dec;3(12):977-9
pubmed: 17099704
FASEB J. 2019 Nov;33(11):12487-12499
pubmed: 31431076
J Biol Chem. 2004 Jan 30;279(5):3197-201
pubmed: 14670965
Membranes (Basel). 2020 Aug 30;10(9):
pubmed: 32872641
Biosens Bioelectron. 2012 Oct-Dec;38(1):362-8
pubmed: 22770903
Photochem Photobiol Sci. 2009 Jun;8(6):847-55
pubmed: 19492113
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635084
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Biosens Bioelectron. 2013 Mar 15;41:642-8
pubmed: 23122229
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30224531
ACS Chem Biol. 2012 Nov 16;7(11):1848-57
pubmed: 22894855
J Virol Methods. 2011 Sep;176(1-2):108-11
pubmed: 21645548
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
JCI Insight. 2020 Oct 2;5(19):
pubmed: 32870820
Biochem J. 2006 Jul 15;397(2):305-12
pubmed: 16551268
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
ACS Chem Biol. 2016 Feb 19;11(2):400-8
pubmed: 26569370
Nat Commun. 2018 Mar 13;9(1):1061
pubmed: 29535383
Anal Bioanal Chem. 2014 Sep;406(23):5541-60
pubmed: 25002334

Auteurs

Taha Azad (T)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

Ragunath Singaravelu (R)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

Emily E F Fekete (EEF)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

Zaid Taha (Z)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

Reza Rezaei (R)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

Rozanne Arulanandam (R)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada.

Stephen Boulton (S)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

Jean-Simon Diallo (JS)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

Carolina S Ilkow (CS)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.

John C Bell (JC)

Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada. Electronic address: jbell@ohri.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH